New Insights toward Colorectal Cancer Chemotherapy Using Natural Bioactive Compounds

被引:128
作者
Redondo-Blanco, Saul [1 ]
Fernandez, Javier [1 ]
Gutierrez-del-Rio, Ignacio [1 ]
Villar, Claudio J. [1 ]
Lombo, Felipe [1 ]
机构
[1] Univ Oviedo, Inst Univ Oncol Principado Asturias IUOPA, Fac Med, Area Microbiol,Dept Biol Func, Oviedo, Spain
关键词
RC; nutraceutical; chemotherapy; radiotherapy; combination therapy; apoptosis; FACTOR-KAPPA-B; ENHANCED ANTITUMOR-ACTIVITY; TURMERIC ETHANOLIC EXTRACT; GROWTH-FACTOR RECEPTOR; INHIBITS TUMOR-GROWTH; INDUCED UP-REGULATION; ABERRANT CRYPT FOCI; CELL-CYCLE ARREST; COLON-CANCER; IN-VITRO;
D O I
10.3389/fphar.2017.00109
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Combination therapy consists in the simultaneous administration of a conventional chemotherapy drug (or sometimes, a radiotherapy protocol) together with one or more natural bioactives (usually from plant or fungal origin) of small molecular weight. This combination of anticancer drugs may be applied to cell cultures of tumor cells, or to an animal model for a cancer type (or its xenograft), or to a clinical trial in patients. In this review, we summarize current knowledge describing diverse synergistic effects on colorectal cancer cell cultures, animal models, and clinical trials of various natural bioactives (stilbenes, flavonoids, terpenes, curcumin, and other structural families), which may be important with respect to diminish final doses of the chemotherapy drug, although maintaining its biological effect. This is important as these approaches may help reduce side effects in patients under conventional chemotherapy. Also, these molecules may exerts their synergistic effects via different cell cycle pathways, including different ones to those responsible of resistance phenotypes: transcription factors, membrane receptors, adhesion and structural molecules, cell cycle regulatory components, and apoptosis pathways.
引用
收藏
页数:22
相关论文
共 197 条
[1]   Bcl-2 independence of flavopiridol-induced apoptosis -: Mitochondrial, depolarization in the absence of cytochrome c release [J].
Achenbach, TV ;
Müller, R ;
Slater, EP .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (41) :32089-32097
[2]   (-)-epigallocatechin gallate causes internalization of the epidermal growth factor receptor in human colon cancer cells [J].
Adachi, Seiji ;
Nagao, Tomokazu ;
To, Satoshi ;
Joe, Andrew K. ;
Shimizu, Masahito ;
Matsushima-Nishiwaki, Rie ;
Kozawa, Osamu ;
Moriwaki, Hisataka ;
Maxfield, Frederick R. ;
Weinstein, I. Bernard .
CARCINOGENESIS, 2008, 29 (10) :1986-1993
[3]   (-)-Epigallocatechin gallate downregulates EGF receptor via phosphorylation at Ser1046/1047 by p38 MAPK in colon cancer cells [J].
Adachi, Seiji ;
Shimizu, Masahito ;
Shirakami, Yohei ;
Yamauchi, Junichi ;
Natsume, Hideo ;
Matsushima-Nishiwaki, Rie ;
To, Satoshi ;
Weinstein, I. Bernard ;
Moriwaki, Hisataka ;
Kozawa, Osamu .
CARCINOGENESIS, 2009, 30 (09) :1544-1552
[4]   Curcumin-free turmeric exhibits anti-inflammatory and anticancer activities: Identification of novel components of turmeric [J].
Aggarwal, Bharat B. ;
Yuan, Wei ;
Li, Shiyou ;
Gupta, Subash C. .
MOLECULAR NUTRITION & FOOD RESEARCH, 2013, 57 (09) :1529-1542
[5]  
Ali I, 2014, ANTICANCER RES, V34, P5439
[6]   Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy [J].
Almasan, A ;
Ashkenazi, A .
CYTOKINE & GROWTH FACTOR REVIEWS, 2003, 14 (3-4) :337-348
[7]   Synergistic anti-proliferative effect of resveratrol and etoposide on human hepatocellular and colon cancer cell lines [J].
Amiri, Fatemehsadat ;
Zarnani, Amir-Hassan ;
Zand, Hamid ;
Koohdani, Fariba ;
Jeddi-Tehrani, Mahmood ;
Vafa, Mohammadreza .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2013, 718 (1-3) :34-40
[8]   Bioavailability of curcumin: Problems and promises [J].
Anand, Preetha ;
Kunnumakkara, Ajaikumar B. ;
Newman, Robert A. ;
Aggarwal, Bharat B. .
MOLECULAR PHARMACEUTICS, 2007, 4 (06) :807-818
[9]   In vitro combinatorial anticancer effects of 5-fluorouracil and curcumin loaded N,O-carboxymethyl chitosan nanoparticles toward colon cancer and in vivo pharmacokinetic studies [J].
Anitha, A. ;
Sreeranganathan, Maya ;
Chennazhi, Krishna Prasad ;
Lakshmanan, Vinoth-Kumar ;
Jayakumar, R. .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2014, 88 (01) :238-251
[10]   The cyclin-dependent kinase inhibitor flavopiridol potentiates the effects of topoisomerase I poisons by suppressing rad51 expression in a p53-dependent manner [J].
Arnbrosini, Grazia ;
Seehnan, Sharon L. ;
Qin, Li-Xuan ;
Schwartz, Gary K. .
CANCER RESEARCH, 2008, 68 (07) :2312-2320